Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
OMED's Cash to Debt is ranked higher than
75% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. OMED: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OMED' s Cash to Debt Range Over the Past 10 Years
Min: 326.31  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.14
OMED's Equity to Asset is ranked lower than
90% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OMED: 0.14 )
Ranked among companies with meaningful Equity to Asset only.
OMED' s Equity to Asset Range Over the Past 10 Years
Min: -2.45  Med: 0.30 Max: 0.7
Current: 0.14
-2.45
0.7
Interest Coverage No Debt
OMED's Interest Coverage is ranked higher than
51% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OMED: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OMED' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -1.42
M-Score: -4.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -276.91
OMED's Operating margin (%) is ranked lower than
63% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. OMED: -276.91 )
Ranked among companies with meaningful Operating margin (%) only.
OMED' s Operating margin (%) Range Over the Past 10 Years
Min: -161.06  Med: -90.63 Max: -48.52
Current: -276.91
-161.06
-48.52
Net-margin (%) -274.46
OMED's Net-margin (%) is ranked lower than
64% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. OMED: -274.46 )
Ranked among companies with meaningful Net-margin (%) only.
OMED' s Net-margin (%) Range Over the Past 10 Years
Min: -152.47  Med: -90.09 Max: -47.87
Current: -274.46
-152.47
-47.87
ROE (%) -125.18
OMED's ROE (%) is ranked lower than
86% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. OMED: -125.18 )
Ranked among companies with meaningful ROE (%) only.
OMED' s ROE (%) Range Over the Past 10 Years
Min: -51.43  Med: -51.43 Max: -51.43
Current: -125.18
ROA (%) -33.21
OMED's ROA (%) is ranked lower than
56% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. OMED: -33.21 )
Ranked among companies with meaningful ROA (%) only.
OMED' s ROA (%) Range Over the Past 10 Years
Min: -28.05  Med: -20.49 Max: -12.61
Current: -33.21
-28.05
-12.61
ROC (Joel Greenblatt) (%) -1491.31
OMED's ROC (Joel Greenblatt) (%) is ranked lower than
66% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. OMED: -1491.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OMED' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1038.97  Med: -480.24 Max: -382.73
Current: -1491.31
-1038.97
-382.73
» OMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

OMED Guru Trades in Q4 2014

PRIMECAP Management 218,400 sh (unchged)
Jim Simons 20,675 sh (-48.45%)
» More
Q1 2015

OMED Guru Trades in Q1 2015

Jim Simons Sold Out
PRIMECAP Management 206,293 sh (-5.54%)
» More
Q2 2015

OMED Guru Trades in Q2 2015

Jim Simons 24,942 sh (New)
PRIMECAP Management 190,800 sh (-7.51%)
» More
Q3 2015

OMED Guru Trades in Q3 2015

Jim Simons 67,700 sh (+171.43%)
PRIMECAP Management 190,800 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with OMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.22
OMED's P/B is ranked lower than
85% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. OMED: 11.22 )
Ranked among companies with meaningful P/B only.
OMED' s P/B Range Over the Past 10 Years
Min: 3.52  Med: 8.75 Max: 28.47
Current: 11.22
3.52
28.47
P/S 10.01
OMED's P/S is ranked higher than
50% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. OMED: 10.01 )
Ranked among companies with meaningful P/S only.
OMED' s P/S Range Over the Past 10 Years
Min: 1.03  Med: 14.01 Max: 25.41
Current: 10.01
1.03
25.41
Current Ratio 4.70
OMED's Current Ratio is ranked higher than
51% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. OMED: 4.70 )
Ranked among companies with meaningful Current Ratio only.
OMED' s Current Ratio Range Over the Past 10 Years
Min: 1.89  Med: 5.19 Max: 6.43
Current: 4.7
1.89
6.43
Quick Ratio 4.70
OMED's Quick Ratio is ranked higher than
53% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. OMED: 4.70 )
Ranked among companies with meaningful Quick Ratio only.
OMED' s Quick Ratio Range Over the Past 10 Years
Min: 1.89  Med: 5.19 Max: 6.43
Current: 4.7
1.89
6.43
Days Sales Outstanding 4.17
OMED's Days Sales Outstanding is ranked higher than
94% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. OMED: 4.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.22  Med: 59.49 Max: 65.72
Current: 4.17
0.22
65.72

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.90
OMED's Price/Net Cash is ranked lower than
81% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 5.23 vs. OMED: 17.90 )
Ranked among companies with meaningful Price/Net Cash only.
OMED' s Price/Net Cash Range Over the Past 10 Years
Min: 5.05  Med: 10.72 Max: 31.9
Current: 17.9
5.05
31.9
Price/Net Current Asset Value 15.78
OMED's Price/Net Current Asset Value is ranked lower than
81% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 4.85 vs. OMED: 15.78 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OMED' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.42  Med: 9.38 Max: 28.12
Current: 15.78
4.42
28.12
Price/Tangible Book 11.22
OMED's Price/Tangible Book is ranked lower than
81% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. OMED: 11.22 )
Ranked among companies with meaningful Price/Tangible Book only.
OMED' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.22  Med: 8.50 Max: 19.99
Current: 11.22
4.22
19.99
Price/Median PS Value 0.71
OMED's Price/Median PS Value is ranked higher than
64% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. OMED: 0.71 )
Ranked among companies with meaningful Price/Median PS Value only.
OMED' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.09  Med: 1.01 Max: 1.26
Current: 0.71
0.09
1.26
Earnings Yield (Greenblatt) (%) -72.50
OMED's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. OMED: -72.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OMED' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -81.3  Med: 0.00 Max: 0
Current: -72.5
-81.3
0

More Statistics

Revenue(Mil) $28
EPS $ -2.53
Beta2.07
Short Percentage of Float11.39%
52-Week Range $8.54 - 29.83
Shares Outstanding(Mil)30.11

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:O0M.Germany,
OncoMed Pharmaceuticals Inc was originally incorporated in July 19, 2004 in Delaware. The Company is a clinical development-stage biopharmaceutical company focused on discovering and developing novel protein therapeutics targeting cancer stem cells, or CSCs. CSCs, also known as tumor-initiating cells, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs exhibit certain properties which include the capacity to divide and give rise to new CSCs via self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. It faces competition from many pharmaceutical and biotechnology companies that are also researching and selling products designed to address these markets. The Company has a total of over 400 patents and pending patent applications in our patent portfolio. The Company's product candidates are subject to regulation by the FDA as biologics.
» More Articles for OMED

Headlines

Articles On GuruFocus.com
Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 

More From Other Websites
OncoMed Pharmaceuticals to Present at Upcoming Investor Conferences Feb 04 2016
Why OncoMed Pharmaceuticals (OMED) Stock Might be a Great Pick Feb 01 2016
Celgene's profit misses estimates as costs rise Jan 28 2016
OncoMed Tanks on Phase II Pancreatic Cancer Study Update Jan 27 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of... Jan 25 2016
OncoMed Pharma downgraded by Leerink Partners Jan 25 2016
OncoMed (OMED) Stock Plummets on Pancreatic Cancer Drug Trial Results Jan 25 2016
OncoMed Pharma Crashes 40% After Poor Trial Data Jan 25 2016
Why OncoMed’s Update Could Crater the Stock Jan 25 2016
OncoMed stock plunges after negative findings by study monitoring board Jan 25 2016
Independent experts say OncoMed cancer drug unlikely to succeed in study Jan 25 2016
OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial Jan 25 2016
ONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 25 2016
OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial Jan 25 2016
OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the... Jan 22 2016
OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the... Jan 22 2016
OncoMed Pharmaceuticals, Inc. – Value Analysis (NASDAQ:OMED) : January 12, 2016 Jan 12 2016
Celgene, Vertex, Illumina Offer Mixed Outlooks Jan 11 2016
Celgene Numbers Disappoint; New CEO Announced Jan 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK